PP2A perturbation of diosmin-associated apoptosis markers
Cell-based study · Human HA22T hepatocellular carcinoma cells [1]
Okadaic acid and PP2A-Cα siRNA opposed diosmin-associated apoptosis-marker changes. This supports cellular PP2A involvement, without establishing direct binding or purified-enzyme activation.
| Endpoint | Reported result | Reference |
|---|---|---|
| PP2A-Cα, t-BID, Bcl-2, Bax, cytochrome c and caspase-9/-3 protein patterns | qualitative response PP2A inhibition or knockdown attenuated diosmin-associated marker changes | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 80 µM
- Exposure duration
- 24 h diosmin; okadaic acid pretreatment 1 h
- Method
- Western blot after pharmacological or siRNA perturbation
- Vehicle
- DMSO; final concentration never exceeded 0.1%
- Co-treatment
- Okadaic acid 0.05 or 0.1 nM; PP2A-Cα siRNA 100 or 120 nM; non-targeting siRNA 100 nM.
- Reported limits
- No direct PP2A catalytic-activity or binding measurement in this experiment. Exact figure-specific transfection-to-treatment interval is not resolved from shared methods.
Methods and source locations
Compound reported in the paper: Diosmin; Compound label in the paper: Sigma diosmin, CAS 520-27-4, >95% pure
Restricted to the reported material and model; no Adooq lot equivalence or human efficacy established.
Sections 2.1–2.3, 2.7, 2.9, 2.12, 3.3–3.4; Fig. 4A–F, p. 2069
PP2A-Cα, t-BID, Bcl-2, Bax, cytochrome c and caspase-9/-3 protein patterns: Western blot, α-tubulin loading control; non-targeting siRNA control; mean ± SE, n = 3 as reported. — Fig. 4A–F; sections 3.3–3.4